Clinical Trial

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-05-20; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06982820
Lead Sponsor GrayMatters Health Ltd.
Conditions Depressive Disorder, Major
Enrollment 170 participants
Start Date 2025-06-25
Primary Completion 2027-05-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-01